Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

The Indiana case cites regulatory disclosures following company claims about drug progress.

Overview

A federal securities class action, Thomas v. Telix, is filed in the U.S. District Court for the Southern District of Indiana on behalf of investors who bought between Feb. 21 and Aug. 28, 2025.
Plaintiffs allege Telix overstated progress for prostate cancer candidates TLX591 and TLX592 and overstated the reliability and compliance of third‑party manufacturing partners.
Telix disclosed an SEC subpoena on July 22, 2025 concerning its prostate therapeutics disclosures, after which its American Depositary Shares fell over multiple sessions.
On Aug. 28, 2025, Telix announced an FDA Complete Response Letter for TLX250‑CDx citing CMC deficiencies and referencing Form 483 observations for two third‑party facilities, followed by a sharper stock decline.
Multiple firms, including Rosen Law, Hagens Berman, Wolf Haldenstein, The Gross Law Firm and Berger Montague, are soliciting investors, with Jan. 9, 2026 as the deadline to seek lead‑plaintiff status and no class yet certified.